A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

NCT03474107 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

608

Enrollment

INDUSTRY

Sponsor class

Conditions

Ureteral Cancer
Urothelial Cancer
Bladder Cancer

Interventions

DRUG: Enfortumab Vedotin
DRUG: Docetaxel
DRUG: Vinflunine
DRUG: Paclitaxel

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]